“…To further support the notion that huMETCAM/MUC18 was expressed at a low level in NPC tissues, we showed that low levels of huMETCAM/ MUC18 were also expressed in seven established NPC cell lines in comparison with that in a human malignant melanoma cell line, SK-Mel-28, two metastatic human prostate cancer cell lines, DU145 and PC-3, and a human bladder cancer cell line, TSU-Pr1. Taken together, we concluded that the diminishing or the loss of huMETCAM/ MUC18 expression may be a new potential biomarker for emergence of NPC, whereas the re-gain of its expression may be a new potential biomarker for the progression of NPC to malignant stages, in addition to other potential markers for this cancer, such as the loss of E-cadherin and connexin 43 expression (Huang et al, 2001;Li et al, 2004;Yi et al, 2006), the gain of ICAM expression (Yu et al, 2004), and the presence of EBV-specific LMP1 (Tsai et al, 2002;Yoshizaki, 2002).…”